These important findings in pre-clinical models have clinical implications and suggest that inhibition of tmTNF/TNFR2 signaling by lenercept was the molecular basis for the worsening symptoms in MS patients. This evidence concerns the gene TNFRSF1B and myeloid sarcoma.